GlassScriptPhysician profile
Rebecca Sharim
NPI 1669600292
$12,268.59
in general payments reported to CMS, 2019-2025
23 companies · $344 in 2025
The $344 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,239 · 2020: $2,947 · 2021: $2,279 · 2022: $1,697 · 2023: $1,598 · 2024: $1,167 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,408 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,408.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,937.38 | 2019-2025 | Otezla, Tavneos, Enbrel |
| Abbvie INC. | $2,604.73 | 2019-2024 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $1,294.07 | 2019-2024 | Cimzia, Bimzelx |
| Horizon Therapeutics Plc | $981.37 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $813.29 | 2019-2023 | |
| Pfizer INC. | $719.20 | 2019-2023 | |
| Janssen Biotech, INC. | $609.07 | 2019-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $356.13 | 2020-2023 | Saphnelo |
| Celgene Corporation | $326.51 | 2019 | |
| Sobi, INC | $319.76 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.31 | 2019-2023 | Cyltezo |
| Lilly USA, LLC | $202.30 | 2019-2022 | |
| Glaxosmithkline, LLC. | $144.96 | 2019-2023 | Benlysta |
| Aurinia Pharma U.S., INC. | $144.49 | 2021-2024 | Lupkynis |
| Collegium Pharmaceutical, INC. | $144.00 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $133.05 | 2019-2023 | Strensiq |
| Genentech USA, INC. | $75.64 | 2019-2021 | |
| Radius Health, INC. | $63.31 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $53.20 | 2022-2023 | Uptravi, Opsumit |
| Pacira Therapeutics, INC. | $44.31 | 2019 | |
| Medtronic, INC. | $43.07 | 2024 | Signia |
| Organon LLC | $27.69 | 2023 | Renflexis, Hadlima |
| Avion Pharmaceuticals | $12.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Sharim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.